CA1040532A - Process for producing solid bismuth-containing pharmaceutical compositions - Google Patents
Process for producing solid bismuth-containing pharmaceutical compositionsInfo
- Publication number
- CA1040532A CA1040532A CA218,092A CA218092A CA1040532A CA 1040532 A CA1040532 A CA 1040532A CA 218092 A CA218092 A CA 218092A CA 1040532 A CA1040532 A CA 1040532A
- Authority
- CA
- Canada
- Prior art keywords
- dry powder
- bismuth
- pharmaceutical composition
- bi2o3
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 229910052797 bismuth Inorganic materials 0.000 title claims description 15
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 title claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 239000007787 solid Substances 0.000 title claims description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000001694 spray drying Methods 0.000 claims abstract description 11
- 229910021529 ammonia Inorganic materials 0.000 claims abstract description 9
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 6
- WMWLMWRWZQELOS-UHFFFAOYSA-N bismuth(iii) oxide Chemical compound O=[Bi]O[Bi]=O WMWLMWRWZQELOS-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000007916 tablet composition Substances 0.000 claims 3
- 230000000767 anti-ulcer Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 150000001621 bismuth Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000034991 Hiatal Hernia Diseases 0.000 description 1
- 206010020028 Hiatus hernia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960001482 bismuth subnitrate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- YSVBPNGJESBVRM-UHFFFAOYSA-L disodium;4-[(1-oxido-4-sulfonaphthalen-2-yl)diazenyl]naphthalene-1-sulfonate Chemical compound [Na+].[Na+].C1=CC=C2C(N=NC3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)O)=CC=C(S([O-])(=O)=O)C2=C1 YSVBPNGJESBVRM-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- -1 sodium Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA00740385A ZA74385B (en) | 1974-01-18 | 1974-01-18 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1040532A true CA1040532A (en) | 1978-10-17 |
Family
ID=25567281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA218,092A Expired CA1040532A (en) | 1974-01-18 | 1975-01-17 | Process for producing solid bismuth-containing pharmaceutical compositions |
Country Status (18)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU179474B (en) * | 1978-02-24 | 1982-10-28 | Laszlo Gyarmati | Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material |
| PH20649A (en) * | 1981-09-22 | 1987-03-16 | Gist Brocades Nv | Bismuth containing composition and method for the preparation thereof |
| US4801608A (en) * | 1981-09-22 | 1989-01-31 | Gist-Brocades N. V. | Bismuth containing composition and method for the preparation thereof |
| WO1986005981A1 (en) * | 1985-04-18 | 1986-10-23 | Borody Thomas J | Treatment of non-ulcer dyspepsia with bismuth salts |
| US4748113A (en) * | 1985-06-13 | 1988-05-31 | Marshall Barry J | Compositions and methods for the diagnosis of gastrointestinal disorders involving urease |
| US5256684A (en) * | 1985-06-13 | 1993-10-26 | The Procter & Gamble Company | Methods and compositions for the treatment of gastrointestinal disorders |
| ATE81010T1 (de) * | 1985-06-13 | 1992-10-15 | Barry James Marshall | Zusammensetzungen zur behandlung von magendarmst¯rungen. |
| EP0206627B1 (en) * | 1985-06-13 | 1992-08-12 | Barry James Dr. Marshall | Methods for the treatment of gastrointestinal disorders |
| DE3865201D1 (de) * | 1988-10-08 | 1991-10-31 | Pfleger R Chem Fab | Fluessiges, wismuthaltiges arzneipraeparat, verfahren zum herstellen desselben und seine verwendung. |
| DE3901508C2 (de) * | 1989-01-19 | 1994-04-07 | Falk Pharma Gmbh | Arzneimittel auf der Grundlage eines Wismut enthaltenden Präparats in fester Form |
| IT1229502B (it) * | 1989-01-25 | 1991-09-03 | Euroresearch Srl | Composizioni contenenti bismuto idonee per uso terapeutico. |
| IE893167A1 (en) * | 1989-10-04 | 1991-04-24 | Ulso Lab Ltd | Preparation of orally administrable liquids for use in¹therapy |
| IE65964B1 (en) * | 1990-07-20 | 1996-01-24 | Slagel David | Products and processes for the treatment of the alimentary canal |
| US5192752A (en) * | 1991-01-14 | 1993-03-09 | The Procter & Gamble Company | Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate |
| US6426085B1 (en) | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| US6902738B2 (en) | 1994-05-02 | 2005-06-07 | Josman Laboratories, Inc. | Topical oral dosage forms containing bismuth compounds |
| US5834002A (en) | 1994-05-02 | 1998-11-10 | Josman Laboratories, Inc. | Chewing gum containing colloidal bismuth subcitrate |
| US6372784B1 (en) | 1995-02-07 | 2002-04-16 | Josman Laboratories, Inc. | Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
| US6379651B1 (en) | 1995-02-07 | 2002-04-30 | Josman Laboratories | Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases |
| MX9703918A (es) | 1997-05-28 | 1998-11-30 | J Marshall M D Barry | Procedimiento para preparar un producto farmaceutico reactivo para deteccion de desorden gastrointestinal causado por bacteria en el tracto gastrointestinal superior. |
| USD485359S1 (en) | 2001-10-15 | 2004-01-13 | Kimberly-Clark Worldwide, Inc. | Specimen-handling tool |
| US6998250B2 (en) | 2001-10-15 | 2006-02-14 | Donald J. McMichael | Method for detecting Helicobacter pylori |
| US7008777B2 (en) | 2001-10-15 | 2006-03-07 | Barry J. Marshall | System for the detection of urease and method for using same |
| US6929926B2 (en) | 2001-10-15 | 2005-08-16 | Barry J. Marshall | Composition for the detection of gastrointestinal disorders |
| USD467348S1 (en) | 2001-10-15 | 2002-12-17 | Kimberly-Clark Worldwide, Inc. | Diagnostic test carrier |
| USD470597S1 (en) | 2001-12-17 | 2003-02-18 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kit |
| USD469881S1 (en) | 2001-12-17 | 2003-02-04 | Kimberly-Clark Worldwide, Inc. | Two-well diagnostic test kit with specimen-handling tool |
| USD484988S1 (en) | 2001-12-17 | 2004-01-06 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kit with specimen-handling tool |
| USD470241S1 (en) | 2001-12-17 | 2003-02-11 | Kimberly-Clark Worldwide, Inc. | Specimen-handling tool |
| USD471639S1 (en) | 2001-12-17 | 2003-03-11 | Kimberly-Clark Worldwide, Inc. | Tool for handling a specimen |
| USD470596S1 (en) | 2001-12-17 | 2003-02-18 | Kimberly-Clark Worldwide, Inc. | Test kit specimen-handling tool |
| US6783976B2 (en) | 2001-12-21 | 2004-08-31 | Kimberly-Clark Worldwide, Inc. | Carrier and specimen-handling tool for use in diagnostic testing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1288789A (en) * | 1968-12-23 | 1972-09-13 | Willem Jacob Serfontein | Improved bismuth preparations |
| GB1259151A (en) * | 1968-12-23 | 1972-01-05 | Willem Jacob Serfontein | Bismuth complexes |
-
1974
- 1974-01-18 ZA ZA00740385A patent/ZA74385B/xx unknown
-
1975
- 1975-01-14 AU AU77293/75A patent/AU485660B2/en not_active Expired
- 1975-01-16 CH CH51075A patent/CH622947A5/de not_active IP Right Cessation
- 1975-01-16 JP JP50007408A patent/JPS5837284B2/ja not_active Expired
- 1975-01-17 BE BE152481A patent/BE824509A/xx not_active IP Right Cessation
- 1975-01-17 DE DE19752501787 patent/DE2501787A1/de active Granted
- 1975-01-17 CA CA218,092A patent/CA1040532A/en not_active Expired
- 1975-01-17 LU LU71668A patent/LU71668A1/xx unknown
- 1975-01-17 GB GB2146/75A patent/GB1478742A/en not_active Expired
- 1975-01-17 ES ES433908A patent/ES433908A1/es not_active Expired
- 1975-01-17 AT AT31875A patent/AT349150B/de not_active IP Right Cessation
- 1975-01-17 NL NLAANVRAGE7500552,A patent/NL185130C/xx not_active IP Right Cessation
- 1975-01-17 IT IT67104/75A patent/IT1036072B/it active
- 1975-01-17 FI FI750113A patent/FI750113A7/fi not_active Application Discontinuation
- 1975-01-17 SE SE7500501A patent/SE437930B/xx not_active IP Right Cessation
- 1975-01-17 IE IE86/75A patent/IE40361B1/xx unknown
- 1975-01-17 DK DK012675A patent/DK151770C/da not_active IP Right Cessation
- 1975-01-17 FR FR7501521A patent/FR2258177B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU485660B2 (en) | 1977-07-28 |
| JPS50116623A (enrdf_load_stackoverflow) | 1975-09-12 |
| JPS5837284B2 (ja) | 1983-08-15 |
| BE824509A (fr) | 1975-07-17 |
| DE2501787C2 (enrdf_load_stackoverflow) | 1987-11-12 |
| AU7729375A (en) | 1976-07-15 |
| NL7500552A (nl) | 1975-07-22 |
| AT349150B (de) | 1979-03-26 |
| IT1036072B (it) | 1979-10-30 |
| IE40361B1 (en) | 1979-05-09 |
| ATA31875A (de) | 1978-08-15 |
| DK151770B (da) | 1988-01-04 |
| DK12675A (enrdf_load_stackoverflow) | 1975-09-15 |
| ES433908A1 (es) | 1976-11-16 |
| FR2258177B1 (enrdf_load_stackoverflow) | 1978-07-21 |
| CH622947A5 (en) | 1981-05-15 |
| SE7500501L (enrdf_load_stackoverflow) | 1975-07-21 |
| SE437930B (sv) | 1985-03-25 |
| FI750113A7 (enrdf_load_stackoverflow) | 1975-07-19 |
| DE2501787A1 (de) | 1975-07-24 |
| LU71668A1 (enrdf_load_stackoverflow) | 1975-06-24 |
| DK151770C (da) | 1989-11-06 |
| GB1478742A (en) | 1977-07-06 |
| IE40361L (en) | 1975-07-18 |
| NL185130C (nl) | 1990-02-01 |
| FR2258177A1 (enrdf_load_stackoverflow) | 1975-08-18 |
| NL185130B (nl) | 1989-09-01 |
| ZA74385B (en) | 1975-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1040532A (en) | Process for producing solid bismuth-containing pharmaceutical compositions | |
| US4956386A (en) | Pharmaceutical compositions and process for their preparation | |
| US5019563A (en) | Pharmaceutical composition | |
| CA1254143A (en) | Pharmaceutical preparation with a content of ibuprofen, and process for its preparation | |
| US3898328A (en) | Dry stable composition for the treatment of scours and dehydration | |
| EP0011489B1 (en) | An analgesic effervescent powder and process for its preparation | |
| EP0524579B1 (en) | Improved oral dosing formulations of dideoxy purine nucleosides | |
| FI77156C (fi) | Foerfarande foer framstaellning av en fast vismuthaltig komposition. | |
| US4801608A (en) | Bismuth containing composition and method for the preparation thereof | |
| Hillyard et al. | Antacid and antiulcer properties of the polysaccharide chitosan in the rat | |
| US4368197A (en) | Zinc aminophylline and its use in the treatment of bronchospasms | |
| SU1009467A1 (ru) | Средство дл растворени мочевых конкрементов | |
| US4225614A (en) | Method of treatment for mucocutaneous herpes simplex infections | |
| US3928609A (en) | Non-alcoholic theophylline product | |
| JPH09502709A (ja) | エストロン誘導体及びカルシウム塩含有の経口、水溶性製薬組成物 | |
| US2883327A (en) | Reducing the gelation of methylcellulose by the addition of a neutral, water-soluble, amino carboxylic acid and product thereof | |
| RU2589507C1 (ru) | Средство на основе сухого экстракта пустырника и способ его получения | |
| GB2061111A (en) | Long acting pharmaceutical composition | |
| US3655883A (en) | Water soluble magnesium-aluminum antacid composition | |
| JPH0222225A (ja) | 胃酸分泌抑制剤含有固型製剤 | |
| US3993778A (en) | Anti-ulcerogenic pharmaceutical compositions containing a 2-amino-3,5-dibromo-benzylamine and method of use | |
| US2940898A (en) | Aluminum salt antacid compositions and method of using same | |
| JPS58116423A (ja) | メタノプロスタサイクリン製剤組成物 | |
| JPH0322874B2 (enrdf_load_stackoverflow) | ||
| Stone | Pharmaceutical application of ferrous gluconate NF |